GlassScriptPhysician profile
Amanda Lewis
NPI 1972949048
$6,663.59
in general payments reported to CMS, 2019-2025
35 companies · $2,502 in 2025
The $2,502 reported for 2025 was more than what 75% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $192 · 2021: $508 · 2022: $933 · 2023: $758 · 2024: $1,164 · 2025: $2,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,183 · Education: $213 · Consulting Fee: $28.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,183.33 |
| Education | $213.08 |
| Consulting Fee | $28.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,332.57 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Amgen INC. | $625.95 | 2021-2025 | Tezspire, Otezla |
| Pharming Healthcare, INC. | $409.80 | 2019-2025 | Ruconest |
| Grifols USA, LLC | $396.74 | 2021-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $316.99 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Csl Behring | $316.55 | 2023-2025 | Hizentra, Haegarda, Andembry |
| Genentech USA, INC. | $306.76 | 2022-2025 | Xolair |
| Glaxosmithkline, LLC. | $303.66 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $303.57 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $303.38 | 2019-2024 | Yupelri |
| Ars Pharmaceuticals Operations, INC. | $296.75 | 2025 | Neffy |
| Genzyme Corporation | $274.63 | 2019-2025 | |
| Verona Pharma, INC. | $196.70 | 2025 | Ohtuvayre |
| Galderma Laboratories, L.P. | $159.18 | 2025 | Nemluvio |
| Biocryst US Sales Co., LLC | $154.40 | 2021-2025 | Orladeyo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $108.76 | 2021-2025 | |
| Pfizer INC. | $97.24 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $90.98 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $84.34 | 2019-2021 | |
| Abbott Laboratories | $80.69 | 2025 | Cardiomems |
| Optinose US, INC. | $73.65 | 2021-2022 | |
| Abbvie INC. | $60.63 | 2023-2024 | |
| Blueprint Medicines Corporation | $48.33 | 2023-2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.70 | 2022-2024 | |
| Janssen Biotech, INC. | $35.50 | 2025 | Carvykti, Rybrevant |
| Incyte Corporation | $35.30 | 2023-2025 | Opzelura |
| Shire North American Group INC | $32.70 | 2019 | |
| Adma Biomanufacturing LLC | $28.05 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $24.62 | 2025 | Dupixent |
| Kaleo, INC. | $24.36 | 2020 | |
| Revance Therapeutics, INC. | $22.50 | 2024 | Daxxify |
| Cycle Pharmaceuticals INC | $21.40 | 2025 | Sajazir |
| Organon LLC | $21.18 | 2025 | Vtama |
| Biohaven Pharmaceuticals, INC. | $19.98 | 2021 | |
| Ionis Pharmaceuticals, INC. | $17.05 | 2025 | Dawnzera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.